公开(公告)号：US08912192B2

公开(公告)日：2014-12-16

申请号：US13578323

申请日：2011-02-10

申请人： Noriyuki Hirasawa ,  Nobuyoshi Kamikido ,  Akihiko Tasaki ,  Shusei Ito

发明人： Noriyuki Hirasawa ,  Nobuyoshi Kamikido ,  Akihiko Tasaki ,  Shusei Ito

IPC分类号： C07D201/00 ,  A61K31/501 ,  A61K9/20

CPC分类号： A61K31/501 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2095

摘要： Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cmax of a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.

摘要翻译： 公开了一种以pH不依赖的方式释放难溶性药物的缓释制剂。 还公开了一种能够将药剂的Cmax控制在足够量的缓释制剂，因此能够将血液中的药剂的水平维持在长期以来可以期待药效的水平 一段的时间。 具体公开的是持续释放制剂，其特征在于含有4-溴-6- [3-（4-氯苯基）丙氧基] -5-（3-吡啶基甲基氨基）-3（2H） - 哒嗪酮的药用盐， 羟丙甲纤维素 持续释放制剂中的有机酸以小于1质量％的量共混。

公开(公告)号：US20080240456A1

公开(公告)日：2008-10-02

申请号：US12058061

申请日：2008-03-28

申请人： Kosuke Sakamoto ,  Toshio Inoue ,  Akira Takahashi ,  Yasunori Kobayashi ,  Kenji Yamagata ,  Shinji Fukumoto ,  Noriyuki Hirasawa ,  Koji Suzuki

发明人： Kosuke Sakamoto ,  Toshio Inoue ,  Akira Takahashi ,  Yasunori Kobayashi ,  Kenji Yamagata ,  Shinji Fukumoto ,  Noriyuki Hirasawa ,  Koji Suzuki

IPC分类号： G10K11/16

CPC分类号： G10K11/178 ,  G10K2210/1282

摘要： A control characteristics changing unit reads, from an EEPROM, various control parameters in an ANC electronic controller, which correspond to specification information acquired from ECUs. The control characteristics changing unit then outputs control parameters, depending on changed specification information among the read control parameters, as change signals Sm1 through Sm6 to a basic signal generating unit, reference signal generating units, filter coefficient updating units, corrective signal generating units, switches, and variable-gain amplifiers, respectively.

摘要翻译： 控制特征改变单元从EEPROM读取与ANC电子控制器中对应于从ECU获取的规格信息的各种控制参数。 然后，控制特性改变单元根据读取控制参数中的改变的指定信息将改变信号Sm 1至Sm 6的控制参数输出到基本信号生成单元，参考信号生成单元，滤波器系数更新单元，校正信号生成单元 ，开关和可变增益放大器。

公开(公告)号：US20120316177A1

公开(公告)日：2012-12-13

申请号：US13578323

申请日：2011-02-10

申请人： Noriyuki Hirasawa ,  Nobuyoshi Kamikido ,  Akihiko Tasaki ,  Shusei Ito

发明人： Noriyuki Hirasawa ,  Nobuyoshi Kamikido ,  Akihiko Tasaki ,  Shusei Ito

IPC分类号： A61K31/501 ,  A61P11/06

CPC分类号： A61K31/501 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2095

摘要： Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cmax of a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.

摘要翻译： 公开了一种以pH不依赖的方式释放难溶性药物的缓释制剂。 还公开了一种能够将药剂的Cmax控制在足够量的缓释制剂，因此能够将血液中的药剂的水平维持在长期以来可以预期药效的水平 一段的时间。 具体公开的是持续释放制剂，其特征在于含有4-溴-6- [3-（4-氯苯基）丙氧基] -5-（3-吡啶基甲基氨基）-3（2H） - 哒嗪酮的药用盐， 羟丙甲纤维素 持续释放制剂中的有机酸以小于1质量％的量共混。